NCT02339922

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: ACTIVE_NOT_RECRUITING

Phase: PHASE2

Sponsor: University of Washington

Condition: Chronic Lymphocytic Leukemia, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia

Signal summary

Public flags

Status signal: Low Signal

Timeline signals: primary_completion_date_past_signal | long_recruitment_duration_signal

Results signal: Low Signal

Operational burden: rare_population_signal | strict_eligibility_signal

Stopped reason

Context when available

No stop reason available in the current public record.